TuisBHM0 • FRA
add
BACHEM HOLDING AG
Vorige sluiting
€73,40
Dagwisseling
€72,80 - €72,80
Jaarwisseling
€51,25 - €81,50
Markkapitalisasie
5,15 mjd CHF
Gemiddelde volume
23,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
SWX
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CHF) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 191,04 m | 4,70% |
Bedryfskoste | 4,65 m | -61,22% |
Netto inkomste | 49,35 m | 17,36% |
Netto winsgrens | 25,83 | 12,11% |
Wins per aandeel | — | — |
EBITDA | 63,83 m | 9,45% |
Effektiewe belastingkoers | 1,53% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CHF) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 30,99 m | -67,45% |
Totale bates | 2,11 mjd | 9,66% |
Totale aanspreeklikheid | 650,41 m | 22,28% |
Totale ekwiteit | 1,46 mjd | — |
Uitstaande aandele | 74,94 m | — |
Prys om te bespreek | 3,77 | — |
Opbrengs op bates | 5,95% | — |
Opbrengs op kapitaal | 8,26% | — |
Kontantvloei
Netto kontantverandering
| (CHF) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 49,35 m | 17,36% |
Kontant van bedrywe | 92,80 m | 220,31% |
Kontant van beleggings | -89,05 m | -624,68% |
Kontant van finansiering | -2,81 m | -391,01% |
Netto kontantverandering | 923,00 k | -94,31% |
Beskikbare kontantvloei | -43,10 m | -92,30% |
Meer oor
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients. The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG.
The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz, Vista and Torrance, and St Helens, as well as a sales and distribution site in Tokyo.
Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies.
In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States.
At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million. Wikipedia
HUB
Gestig
1971
Webwerf
Werknemers
2 363